Key Highlights

  • Alvotech (NASDAQ: ALVO) received FDA approval for an updated SIMLANDI Manufacturing protocol
  • The protocol change doubles batch production yields of adalimumab drug substance without scaling up Upstream operations
  • Approval frees Facility capacity for pipeline Biosimilars and strengthens Supply resilience
  • Company says the change supports product margins and commercial scalability across partnered markets

Article

Alvotech (NASDAQ: ALVO) secured FDA approval for an updated manufacturing protocol for SIMLANDI, its adalimumab biosimilar, a change the company said effectively doubles batch production yields of the drug substance without requiring upstream operations to be scaled up.

Manufacturing Efficiency Gains

The approved protocol update allows Alvotech (NASDAQ: ALVO) to extract significantly more drug substance from each production run of SIMLANDI, the company’s biosimilar referencing Humira (adalimumab), a widely used anti-inflammatory biologic historically prescribed for conditions including rheumatoid arthritis, psoriasis and inflammatory bowel disease. By doubling output per batch without new Capital Investment in upstream capacity, the approval improves the unit Economics of Alvotech’s existing manufacturing infrastructure.

Alvotech (NASDAQ: ALVO) said the efficiency gain also frees up facility capacity that can be redirected toward other biosimilars in its pipeline, a consideration that matters for a company competing in a biosimilar market where manufacturing scale increasingly determines competitiveness against both originator Biologics and rival biosimilar developers.

Supply Resilience and Commercial Impact

Beyond the immediate Yield improvement, Alvotech (NASDAQ: ALVO) said the approval strengthens supply resilience for SIMLANDI, reducing the risk of production bottlenecks as commercial Demand for the adalimumab biosimilar scales across its international markets.

Supply reliability has become a differentiating Factor in the adalimumab biosimilar category, where multiple competing products have launched in the US market following the 2023 patent-related entry window on Humira, and distribution partners and payers have shown a preference for suppliers able to guarantee consistent volume.

The company said the manufacturing update also supports product margins, given that doubling yield per batch lowers the per-unit cost of goods without a corresponding increase in fixed manufacturing costs — an outcome that compounds as commercial volumes increase across Alvotech’s (NASDAQ: ALVO) partnered markets.

Pipeline and Competitive Positioning

Alvotech (NASDAQ: ALVO) develops biosimilar versions of complex biologic medicines through partnerships with commercial distributors across multiple geographies, positioning manufacturing scale and cost efficiency as central to its competitive strategy against both originator products and other biosimilar entrants.

The company said the newly approved SIMLANDI protocol reflects an ongoing effort to optimize its existing manufacturing footprint ahead of further pipeline biosimilar launches, rather than a one-time adjustment tied solely to the adalimumab program.

The SIMLANDI approval follows a broader pattern in Alvotech’s (NASDAQ: ALVO) manufacturing strategy, under which the company has sought incremental process improvements across its biosimilar portfolio rather than relying solely on new facility construction to add capacity. Yield-focused protocol changes of this kind typically require extensive analytical and comparability data to satisfy regulators that the resulting drug substance remains equivalent to the originally approved process, a bar Alvotech (NASDAQ: ALVO) said its updated SIMLANDI protocol has now cleared.

Alvotech (NASDAQ: ALVO) said it will continue to evaluate similar process-efficiency opportunities across its manufacturing network as it works to support both existing commercial products and the biosimilars still advancing through its development pipeline.